Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs

Ute Jungwirth, Dimitris N. Xanthos, Johannes Gojo, Anna K. Bytzek, Wilfried Körner, Petra Heffeter, Sergey A. Abramkin, Michael A. Jakupec, Christian G. Hartinger, Ursula Windberger, Markus Galanski, Bernhard K. Keppler and Walter Berger
Molecular Pharmacology May 2012, 81 (5) 719-728; DOI: https://doi.org/10.1124/mol.111.077321
Ute Jungwirth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitris N. Xanthos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Gojo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna K. Bytzek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilfried Körner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petra Heffeter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey A. Abramkin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Jakupec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian G. Hartinger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ursula Windberger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Galanski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard K. Keppler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Berger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

Oxaliplatin is successfully used in systemic cancer therapy. However, resistance development and severe adverse effects are limiting factors for curative cancer treatment with oxaliplatin. The purpose of this study was to comparatively investigate in vitro and in vivo anticancer properties as well as the adverse effects of two methyl-substituted enantiomerically pure oxaliplatin analogs [[(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine] oxalatoplatinum(II) (KP1537), and [(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine]oxalatoplatinum(II) (KP1691)] and to evaluate the impact of stereoisomerism. Although the novel oxaliplatin analogs demonstrated in multiple aspects activities comparable with those of the parental compound, several key differences were discovered. The analogs were characterized by reduced vulnerability to resistance mechanisms such as p53 mutations, reduced dependence on immunogenic cell death induction, and distinctly attenuated adverse effects including weight loss and cold hyperalgesia. Stereoisomerism of the substituted methyl group had a complex and in some aspects even contradictory impact on drug accumulation and anticancer activity both in vitro and in vivo. To summarize, methyl-substituted oxaliplatin analogs harbor improved therapeutic characteristics including significantly reduced adverse effects. Hence, they might be promising metal-based anticancer drug candidates for further (pre)clinical evaluation.

Footnotes

  • ↵Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

  • This work was supported by the Fonds zur Förderung der wissenschaftlichen Forschung [Grant FWF L568], Forschungsförderungsgesellschaft, the Genome Austria (GENAU) program (PLACEBO-Platform Austria for Chemical Biology) of the Austrian Council for Research and Technology Development.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

    http://dx.doi.org/10.1124/mol.111.077321.

  • ABBREVIATIONS:

    DACH
    cyclohexanediamine
    KP1537
    [(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine]oxalatoplatinum(II)
    KP1691
    [(1R,2R,4S)-4-methyl-1,2-cyclohexanediamine]oxalatoplatinum(II)
    MTT
    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
    PI
    propidium iodide
    ANOVA
    analysis of variance
    wt
    wild-type
    ko
    knockout
    oxR
    oxaliplatin-resistant cells.

  • Received December 22, 2011.
  • Accepted February 13, 2012.
  • Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 81 (5)
Molecular Pharmacology
Vol. 81, Issue 5
1 May 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Anticancer Activity of Oxaliplatin Analogs

Ute Jungwirth, Dimitris N. Xanthos, Johannes Gojo, Anna K. Bytzek, Wilfried Körner, Petra Heffeter, Sergey A. Abramkin, Michael A. Jakupec, Christian G. Hartinger, Ursula Windberger, Markus Galanski, Bernhard K. Keppler and Walter Berger
Molecular Pharmacology May 1, 2012, 81 (5) 719-728; DOI: https://doi.org/10.1124/mol.111.077321

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Anticancer Activity of Oxaliplatin Analogs

Ute Jungwirth, Dimitris N. Xanthos, Johannes Gojo, Anna K. Bytzek, Wilfried Körner, Petra Heffeter, Sergey A. Abramkin, Michael A. Jakupec, Christian G. Hartinger, Ursula Windberger, Markus Galanski, Bernhard K. Keppler and Walter Berger
Molecular Pharmacology May 1, 2012, 81 (5) 719-728; DOI: https://doi.org/10.1124/mol.111.077321
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • TRPV3 and TRPV4 Channels Coassemble into Heterotetramers
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics